Pfizer Inc (New York, NY) has received FDA approval for the intravenous antifungal Eraxis for the treatment of candidemia, a potentially life-threatening bloodstream infection, and for the treatment of 2 other Candida infections, peritonitis and intra-abdominal abscesses. The product also is approved for the treatment of esophageal candidiasis. The recommended dose for candidemia and other Candida infections is a single 200-mg loading dose of Eraxis on day 1, followed by a 100-mg daily dose thereafter. The recommended dose for esophageal candidiasis is a single 100-mg loading dose of Eraxis on day 1, followed by a 50-mg daily dose thereafter. Eraxis is available in 50-mg single-use vials of sterile, lyophilized, preservative-free powder. The companion single-use diluent vials contain 15 mL of 20% (w/w) dehydrated alcohol in water for injection. For more information, visit www.eraxisrx.com, or call 800-438-1985.